# Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

> **NCT00192517** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 44 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** MEDI-522
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00192517
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-08
- **Final completion:** 2004-09
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2009-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192517, "Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00192517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*